AstraZeneca and Galderma Form R&D Collaboration

Under the terms of the agreement, Galderma will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications.

AstraZeneca and Galderma Pharma S.A. announced they have reached a R&D collaboration for the development of new treatments for dermatological diseases including psoriasis, acne and atopic dermatitis.

Under the terms of the agreement, Galderma, a global speciality pharmaceutical company focused on dermatology, will have exclusive access to a number of compounds from across AstraZeneca’s portfolio to develop in dermatological indications. Initial targets for collaboration have already been identified from disease areas as diverse as oncology, inflammation and central nervous system. These will be interrogated based on translational science and pre-clinical testing to determine the ones that will progress in the collaboration. The financial terms of the five-year agreement wer